Matthew R. Pratt

Find an error

Name: Pratt, Matthew R.
Organization: University of Southern California , USA
Department: Department of Chemistry
Title: (PhD)

TOPICS

Co-reporter:Kelly N. Chuh, Anna R. Batt, Balyn W. Zaro, Narek Darabedian, Nicholas P. Marotta, Caroline K. Brennan, Arya Amirhekmat, and Matthew R. Pratt
Journal of the American Chemical Society June 14, 2017 Volume 139(Issue 23) pp:7872-7872
Publication Date(Web):May 22, 2017
DOI:10.1021/jacs.7b02213
O-GlcNAc modification (O-GlcNAcylation) is required for survival in mammalian cells. Genetic and biochemical experiments have found that increased modification inhibits apoptosis in tissues and cell culture and that lowering O-GlcNAcylation induces cell death. However, the molecular mechanisms by which O-GlcNAcylation might inhibit apoptosis are still being elucidated. Here, we first synthesize a new metabolic chemical reporter, 6-Alkynyl-6-deoxy-GlcNAc (6AlkGlcNAc), for the identification of O-GlcNAc-modified proteins. Subsequent characterization of 6AlkGlcNAc shows that this probe is selectively incorporated into O-GlcNAcylated proteins over cell-surface glycoproteins. Using this probe, we discover that the apoptotic caspases are O-GlcNAcylated, which we confirmed using other techniques, raising the possibility that the modification affects their biochemistry. We then demonstrate that changes in the global levels of O-GlcNAcylation result in a converse change in the kinetics of caspase-8 activation during apoptosis. Finally, we show that caspase-8 is modified at residues that can block its cleavage/activation. Our results provide the first evidence that the caspases may be directly affected by O-GlcNAcylation as a potential antiapoptotic mechanism.
Co-reporter:Cesar A. De Leon, Paul M. Levine, Timothy W. Craven, and Matthew R. Pratt
Biochemistry July 11, 2017 Volume 56(Issue 27) pp:3507-3507
Publication Date(Web):June 19, 2017
DOI:10.1021/acs.biochem.7b00268
Synthetic proteins bearing site-specific posttranslational modifications have revolutionized our understanding of their biological functions in vitro and in vivo. One such modification, O-GlcNAcylation, is the dynamic addition of β-N-acetyl glucosamine to the side chains of serine and threonine residues of proteins, yet our understanding of the site-specific impact of O-GlcNAcylation remains difficult to evaluate in vivo because of the potential for enzymatic removal by endogenous O-GlcNAcase (OGA). Thioglycosides are generally perceived to be enzymatically stable structural mimics of O-GlcNAc; however, in vitro experiments with small-molecule GlcNAc thioglycosides have demonstrated that OGA can hydrolyze these linkages, indicating that S-linked β-N-acetyl glucosamine (S-GlcNAc) on peptides or proteins may not be completely stable. Here, we first develop a robust synthetic route to access an S-GlcNAcylated cysteine building block for peptide and protein synthesis. Using this modified amino acid, we establish that S-GlcNAc is an enzymatically stable surrogate for O-GlcNAcylation in its native protein setting. We also applied nuclear magnetic resonance spectroscopy and computational modeling to find that S-GlcNAc is an good structural mimic of O-GlcNAc. Finally, we demonstrate that site-specific S-GlcNAcylation results in biophysical characteristics that are the same as those of O-GlcNAc within the context of the protein α-synuclein. While this study is limited in focus to two model systems, these data suggest that S-GlcNAc broadly resembles O-GlcNAc and that it is indeed a stable analogue in the context of peptides and proteins.
Co-reporter:Yuka E. Lewis, Ana Galesic, Paul M. Levine, Cesar A. De Leon, Natalie Lamiri, Caroline K. Brennan, and Matthew R. Pratt
ACS Chemical Biology April 21, 2017 Volume 12(Issue 4) pp:1020-1020
Publication Date(Web):February 14, 2017
DOI:10.1021/acschembio.7b00113
The aggregation of neurodegenerative-disease associated proteins can be affected by many factors, including a variety of post-translational modifications. One such modification, O-GlcNAcylation, has been found on some of these aggregation prone proteins, including α-synuclein, the major protein that plays a causative role in synucleinopathies like Parkinson’s disease. We previously used synthetic protein chemistry to prepare α-synuclein bearing a homogeneous O-GlcNAc modification at threonine 72 and showed that this modification inhibits protein aggregation. However, the effects of the other eight O-GlcNAcylation sites that have been identified were unknown. Here, we use a similar synthetic strategy to investigate the consequences of this modification at one of these sites, serine 87. We show that O-GlcNAcylation at this site also inhibits α-synuclein aggregation but to a lesser extent than that for the same modification at threonine 72. However, we also find that this modification does not affect the membrane-binding properties of α-synuclein, which differentiates it from phosphorylation at the same site. These results further support the development of therapies that can elevate O-GlcNAcylation of α-synuclein to slow the progression of Parkinson’s disease.
Co-reporter:Paul M. Levine, Cesar A. De Leon, Ana Galesic, Aaron Balana, Nicholas P. Marotta, Yuka E. Lewis, Matthew R. Pratt
Bioorganic & Medicinal Chemistry 2017 Volume 25, Issue 18(Issue 18) pp:
Publication Date(Web):15 September 2017
DOI:10.1016/j.bmc.2017.04.038
The major protein associated with Parkinson’s disease (PD) is α-synuclein, as it can form toxic amyloid-aggregates that are a hallmark of many neurodegenerative diseases. α-Synuclein is a substrate for several different posttranslational modifications (PTMs) that have the potential to affect its biological functions and/or aggregation. However, the biophysical effects of many of these modifications remain to be established. One such modification is the addition of the monosaccharide N-acetyl-glucosamine, O-GlcNAc, which has been found on several α-synuclein serine and threonine residues in vivo. We have previously used synthetic protein chemistry to generate α-synuclein bearing two of these physiologically relevant O-GlcNAcylation events at threonine 72 and serine 87 and demonstrated that both of these modifications inhibit α-synuclein aggregation. Here, we use the same synthetic protein methodology to demonstrate that these same O-GlcNAc modifications also inhibit the cleavage of α-synuclein by the protease calpain. This further supports a role for O-GlcNAcylation in the modulation of α-synuclein biology, as proteolysis has been shown to potentially affect both protein aggregation and degradation.Download high-res image (173KB)Download full-size image
Co-reporter:Yuka E. Lewis, Tharindumala Abeywardana, Yu Hsuan Lin, Ana Galesic, and Matthew R. Pratt
ACS Chemical Biology 2016 Volume 11(Issue 4) pp:931
Publication Date(Web):January 4, 2016
DOI:10.1021/acschembio.5b01042
The reversible modification of protein by the small protein ubiquitin and other ubiquitin-like modifiers plays important roles in virtually every key biological process in eukaryotic cells. The establishment of a range of chemical methods for the preparation of ubiquitinated proteins has enabled the site-specific interrogation of the consequences of these modifications. However, many of these techniques require significant levels of synthetic expertise, somewhat limiting their widespread application by the biological community. To overcome this issue, the creation of structural analogues of the ubiquitin–protein linkage that can be readily prepared with commercially available reagents and buffers is an important goal. Here we present the development of conditions for the facile synthesis of bis-thio-acetone (BTA) linkages of ubiquitinated proteins in high yields. Additionally, we apply this technique to the preparation of the aggregation prone protein α-synuclein bearing either ubiquitin or the small ubiquitin-like modifier (SUMO). With these proteins, we demonstrate that the BTA linkage recapitulates the previously published effects of either of these proteins on α-synuclein, suggesting that it is a good structural mimic. Notably, the BTA linkage is chemically and enzymatically stable, enabling us to study the consequences of site-specific ubiquitination and SUMOylation on the toxicity of α-synuclein in cell culture, which revealed modification and site-specific differences.
Co-reporter:Kelly N Chuh, Matthew R Pratt
Current Opinion in Chemical Biology 2015 Volume 24() pp:27-37
Publication Date(Web):February 2015
DOI:10.1016/j.cbpa.2014.10.020
•Posttranslational modifications (PTMs) increase the chemical diversity of proteins.•The unbiased identification of some PTM substrates remains challenging.•Several chemical methods have been developed to tackle this challenge.Thousands of proteins are subjected to posttranslational modifications that can have dramatic effects on their functions. Traditional biological methods have struggled to address some of the challenges inherit in the unbiased identification of certain posttranslational modifications. As with many areas of biological discovery, the development of chemoselective and bioorthogonal reactions and chemical probes has transformed our ability to selectively label and enrich a wide variety of posttranslational modifications. Collectively, these efforts are making significant contributions to the goal of mapping the protein modification landscape.
Co-reporter:Tharindumala Abeywardana and Matthew R. Pratt
Biochemistry 2015 Volume 54(Issue 4) pp:959-961
Publication Date(Web):January 19, 2015
DOI:10.1021/bi501512m
α-Synuclein, the major aggregating protein in Parkinson’s disease, can be modified by the small protein SUMO, indicating a potential role in disease. However, the effects of SUMOylation on α-synuclein aggregation remain controversial due to heterogeneous nature of the proteins previously investigated. Here we used protein semisynthesis to obtain homogeneously SUMOylated α-synuclein and discovered site- and isoform-dependent effects of SUMOylation on α-synuclein aggregation. Our results indicate that SUMOylation at K102 is a better inhibitor of aggregation than corresponding modification at K96 and SUMO1 modification, a better inhibitor than SUMO3.
Co-reporter:Kelly N. Chuh
Glycoconjugate Journal 2015 Volume 32( Issue 7) pp:443-454
Publication Date(Web):2015 October
DOI:10.1007/s10719-015-9589-3
The majority of cell-surface and secreted proteins are glycosylated, which can directly affect their macromolecular interactions, stability, and localization. Investigating these effects is critical to developing a complete understanding of the role of glycoproteins in fundamental biology and human disease. The development of selective and unique chemical reactions have revolutionized the visualization, identification, and characterization of glycoproteins. Here, we review the chemical methods that have been created to enable the visualization of the major types of cell-surface glycoproteins in living systems, from mammalian cells to whole animals.
Co-reporter:Kelly N. Chuh ; Balyn W. Zaro ; Friedrich Piller ; Véronique Piller
Journal of the American Chemical Society 2014 Volume 136(Issue 35) pp:12283-12295
Publication Date(Web):August 20, 2014
DOI:10.1021/ja504063c
Metabolic chemical reporters (MCRs) of glycosylation are analogues of monosaccharides that contain bioorthogonal functionalities and enable the direct visualization and identification of glycoproteins from living cells. Each MCR was initially thought to report on specific types of glycosylation. We and others have demonstrated that several MCRs are metabolically transformed and enter multiple glycosylation pathways. Therefore, the development of selective MCRs remains a key unmet goal. We demonstrate here that 6-azido-6-deoxy-N-acetyl-glucosamine (6AzGlcNAc) is a specific MCR for O-GlcNAcylated proteins. Biochemical analysis and comparative proteomics with 6AzGlcNAc, N-azidoacetyl-glucosamine (GlcNAz), and N-azidoacetyl-galactosamine (GalNAz) revealed that 6AzGlcNAc exclusively labels intracellular proteins, while GlcNAz and GalNAz are incorporated into a combination of intracellular and extracellular/lumenal glycoproteins. Notably, 6AzGlcNAc cannot be biosynthetically transformed into the corresponding UDP sugar-donor by the canonical salvage-pathway that requires phosphorylation at the 6-hydroxyl. In vitro experiments showed that 6AzGlcNAc can bypass this roadblock through direct phosphorylation of its 1-hydroxyl by the enzyme phosphoacetylglucosamine mutase (AGM1). Taken together, 6AzGlcNAc enables the specific analysis of O-GlcNAcylated proteins, and these results suggest that specific MCRs for other types of glycosylation can be developed. Additionally, our data demonstrate that cells are equipped with a somewhat unappreciated metabolic flexibility with important implications for the biosynthesis of natural and unnatural carbohydrates.
Co-reporter:Balyn W. Zaro, Kelly N. Chuh, and Matthew R. Pratt
ACS Chemical Biology 2014 Volume 9(Issue 9) pp:1991
Publication Date(Web):July 25, 2014
DOI:10.1021/cb5005564
Metabolic chemical reporters have been largely used to study posttranslational modifications. Generally, it was assumed that these reporters entered one biosynthetic pathway, resulting in labeling of one type of modification. However, because they are metabolized by cells before their addition onto proteins, metabolic chemical reporters potentially provide a unique opportunity to read-out on both modifications of interest and cellular metabolism. We report here the development of a metabolic chemical reporter 1-deoxy-N-pentynyl glucosamine (1-deoxy-GlcNAlk). This small-molecule cannot be incorporated into glycans; however, treatment of mammalian cells results in labeling of a variety proteins and enables their visualization and identification. Competition of this labeling with sodium acetate and an acetyltransferase inhibitor suggests that 1-deoxy-GlcNAlk can enter the protein acetylation pathway. These results demonstrate that metabolic chemical reporters have the potential to isolate and potentially discover cross-talk between metabolic pathways in living cells.
Co-reporter:Tharindumala Abeywardana; Dr. Matthew R. Pratt
ChemBioChem 2014 Volume 15( Issue 11) pp:1547-1554
Publication Date(Web):
DOI:10.1002/cbic.201402117

Abstract

Chemistry has long played an indispensable role in biological discovery through the synthesis of homogeneous, structurally defined material. With continuing advances in the area of synthetic protein chemistry, chemists are able to prepare increasingly large and complex proteins that have enabled key biochemical experiments. Here, we describe some of the chemical methods that have been applied to the synthesis of ubiquitylated proteins, as ubiquitylation is a crucial post-translational modification that mediates a variety of important biological effects on substrate proteins.

Co-reporter:Yu Hsuan Lin; Dr. Matthew R. Pratt
ChemBioChem 2014 Volume 15( Issue 6) pp:805-809
Publication Date(Web):
DOI:10.1002/cbic.201400006

Abstract

One of the most successful strategies for controlling protein concentrations in living cells relies on protein destabilization domains (DD). Under normal conditions, a DD will be rapidly degraded by the proteasome. However, the same DD can be stabilized or “shielded” in a stoichiometric complex with a small molecule, enabling dose-dependent control of its concentration. This process has been exploited by several labs to post-translationally control the expression levels of proteins in vitro as well as in vivo, although the previous technologies resulted in permanent fusion of the protein of interest to the DD, which can affect biological activity and complicate results. We previously reported a complementary strategy, termed traceless shielding (TShld), in which the protein of interest is released in its native form. Here, we describe an optimized protein concentration control system, TTShld, which retains the traceless features of TShld but utilizes two tiers of small molecule control to set protein concentrations in living cells. These experiments provide the first protein concentration control system that results in both a wide range of protein concentrations and proteins free from engineered fusion constructs. The TTShld system has a greatly improved dynamic range compared to our previously reported system, and the traceless feature is attractive for elucidation of the consequences of protein concentration in cell biology.

Co-reporter:Leslie A. Bateman ; Balyn W. Zaro ; Stephanie M. Miller
Journal of the American Chemical Society 2013 Volume 135(Issue 39) pp:14568-14573
Publication Date(Web):September 2, 2013
DOI:10.1021/ja408322b
Aspirin (acetylsalicylic acid) is widely used for the acute treatment of inflammation and the management of cardiovascular disease. More recently, it has also been shown to reduce the risk of a variety of cancers. The anti-inflammatory properties of aspirin in pain-relief, cardio-protection, and chemoprevention are well-known to result from the covalent inhibition of cyclooxygenase enzymes through nonenzymatic acetylation of key serine residues. However, any additional molecular mechanisms that may contribute to the beneficial effects of aspirin remain poorly defined. Interestingly, studies over the past 50 years using radiolabeled aspirin demonstrated that other proteins are acetylated by aspirin and enrichment with antiacetyl-lysine antibodies identified 33 potential targets of aspirin-dependent acetylation. Herein we describe the development of an alkyne-modified aspirin analogue (AspAlk) as a chemical reporters of aspirin-dependent acetylation in living cells. When combined with the Cu(I)-catalyzed [3 + 2] azide–alkyne cycloaddition, this chemical reporter allowed for the robust in-gel fluorescent detection of acetylation and the subsequent enrichment and identification of 120 proteins, 112 of which have not been previously reported to be acetylated by aspirin in cellular or in vivo contexts. Finally, AspAlk was shown to modify the core histone proteins, implicating aspirin as a potential chemical-regulator of transcription.
Co-reporter:Leslie A. Bateman, Balyn W. Zaro, Kelly N. Chuh and Matthew R. Pratt  
Chemical Communications 2013 vol. 49(Issue 39) pp:4328-4330
Publication Date(Web):03 Dec 2012
DOI:10.1039/C2CC37963E
Metabolic chemical reporters of glycosylation allow for the visualization and identification of a variety of glycoconjugates by taking advantage of the promiscuity of carbohydrate metabolism. Here we describe the synthesis and characterization of metabolic chemical reporters bearing an N-propargyloxycarbamate (Poc) group that creates discrimination between glycosylation pathways.
Co-reporter:Tharindumala Abeywardana, Yu Hsuan Lin, Ruth Rott, Simone Engelender, Matthew R. Pratt
Chemistry & Biology 2013 Volume 20(Issue 10) pp:1207-1213
Publication Date(Web):24 October 2013
DOI:10.1016/j.chembiol.2013.09.009
•Nine monoubiquitinated α-synuclein proteins were prepared semisynthetically•Monoubiquitination toward the N terminus resulted in degradation by the proteasome•Three sites of modification did not result in α-synuclein degradation•There are site-specific differences in monoubiuqitin-mediated protein degradationThe formation of toxic aggregates composed largely of the protein α-synuclein are a hallmark of Parkinson’s disease. Evidence from both early-onset forms of the disease in humans and animal models has shown that the progression of the disease is correlated with the expression levels of α-synuclein, suggesting that cellular mechanisms that degrade excess α-synuclein are key. We and others have shown that monoubiquitinated α-synuclein can be degraded by the 26S proteasome; however, the contributions of each of the nine known individual monoubiquitination sites were unknown. Herein, we determined the consequences of each of the modification sites using homogenous, semisynthetic proteins in combination with an in vitro proteasome turnover assay. The data suggest that the site-specific effects of monoubiquitination support different levels of α-synuclein degradation.Figure optionsDownload full-size imageDownload high-quality image (199 K)Download as PowerPoint slide
Co-reporter:Franziska Meier ; Tharindumala Abeywardana ; Abhinav Dhall ; Nicholas P. Marotta ; Jobin Varkey ; Ralf Langen ; Champak Chatterjee
Journal of the American Chemical Society 2012 Volume 134(Issue 12) pp:5468-5471
Publication Date(Web):March 10, 2012
DOI:10.1021/ja300094r
The process of neurodegeneration in Parkinson’s Disease is intimately associated with the aggregation of the protein α-synuclein into toxic oligomers and fibrils. Interestingly, many of these protein aggregates are found to be post-translationally modified by ubiquitin at several different lysine residues. However, the inability to generate homogeneously ubiquitin modified α-synuclein at each site has prevented the understanding of the specific biochemical consequences. We have used protein semisynthesis to generate nine site-specifically ubiquitin modified α-synuclein derivatives and have demonstrated that different ubiquitination sites have differential effects on α-synuclein aggregation.
Co-reporter:Matthew R. Pratt
Chemistry & Biology 2012 Volume 19(Issue 9) pp:1084-1085
Publication Date(Web):21 September 2012
DOI:10.1016/j.chembiol.2012.09.001
Small molecules that inhibit common cancer-associated changes in metabolism have great potential as widely applicable therapies. In this issue of Chemistry & Biology, Kung et al. report the characterization of a small molecule activator of the enzyme pyruvate kinase M2, which reprograms cancer cell metabolism resulting in dependence on the amino acid serine.
Co-reporter:Nicholas P. Marotta;Carli A. Cherwien;Tharindumala Abeywardana ; Dr. Matthew R. Pratt
ChemBioChem 2012 Volume 13( Issue 18) pp:2665-2670
Publication Date(Web):
DOI:10.1002/cbic.201200478
Co-reporter:Balyn W. Zaro, Leslie A. Bateman, Matthew R. Pratt
Bioorganic & Medicinal Chemistry Letters 2011 Volume 21(Issue 17) pp:5062-5066
Publication Date(Web):1 September 2011
DOI:10.1016/j.bmcl.2011.04.038
Mucin-type O-linked glycosylation is a common post translational modification of cell-surface and secretory pathway proteins and is implicated in vital biological processes as well as human disease. We report here the use of the metabolic chemical reporter GalNAz along with Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition conditions for the robust, in-gel fluorescent visualization of mucin-type O-linked glycoproteins.
Co-reporter:Balyn W. Zaro;Yu-Ying Yang;Howard C. Hang
PNAS 2011 Volume 108 (Issue 20 ) pp:8146-8151
Publication Date(Web):2011-05-17
DOI:10.1073/pnas.1102458108
The dynamic modification of nuclear and cytoplasmic proteins by the monosaccharide N-acetyl-glucosamine (GlcNAc) continues to emerge as an important regulator of many biological processes. Herein we describe the development of an alkynyl-modified GlcNAc analog (GlcNAlk) as a new chemical reporter of O-GlcNAc modification in living cells. This strategy is based on metabolic incorporation of reactive functionality into the GlcNAc biosynthetic pathway. When combined with the Cu(I)-catalyzed [3 + 2] azide-alkyne cycloaddition, this chemical reporter allowed for the robust in-gel fluorescent visualization of O-GlcNAc and affinity enrichment and identification of O-GlcNAc-modified proteins. Using in-gel fluorescence detection, we characterized the metabolic fates of GlcNAlk and the previously reported azido analog, GlcNAz. We confirmed previous results that GlcNAz can be metabolically interconverted to GalNAz, whereas GlcNAlk does not, thereby yielding a more specific metabolic reporter of O-GlcNAc modification. We also used GlcNAlk, in combination with a biotin affinity tag, to identify 374 proteins, 279 of which were not previously reported, and we subsequently confirmed the enrichment of three previously uncharacterized proteins. Finally we confirmed the O-GlcNAc modification of the ubiquitin ligase NEDD4-1, the first reported glycosylation of this protein.
Co-reporter:Hubert D. Lau;Junko Yaegashi;Balyn W. Zaro; Matthew R. Pratt
Angewandte Chemie 2010 Volume 122( Issue 45) pp:8636-8639
Publication Date(Web):
DOI:10.1002/ange.201003073
Co-reporter:Hubert D. Lau;Junko Yaegashi;Balyn W. Zaro; Matthew R. Pratt
Angewandte Chemie International Edition 2010 Volume 49( Issue 45) pp:8458-8461
Publication Date(Web):
DOI:10.1002/anie.201003073
Co-reporter:Matthew R. Pratt, Matthew D. Sekedat, Kyle P. Chiang, Tom W. Muir
Chemistry & Biology 2009 Volume 16(Issue 9) pp:1001-1012
Publication Date(Web):25 September 2009
DOI:10.1016/j.chembiol.2009.07.011
Cells control their own death through a program termed apoptosis, which is indispensable for development and homeostasis in all metazoans. Lysosomal cysteine proteases are not normally thought of as participating in apoptosis; however, recent reports have shown that the cathepsin proteases can be released from the lysosome during apoptosis, where they can participate in cell death. We report here the development of an activity-based probe that, under optimized conditions, reports on cathepsin B activity only in apoptotic cells by reading out the release of cathepsin B from the lysosomes. Biochemical characterization of apoptosis in cells from cathepsin B null mice shows delayed and suboptimal activation of caspases. Our data further supports a role for cathepsin B in the cytosol as a positive regulator of a cell death feed-forward loop and provides a chemical tool for future investigations.
Co-reporter:Leslie A. Bateman, Balyn W. Zaro, Kelly N. Chuh and Matthew R. Pratt
Chemical Communications 2013 - vol. 49(Issue 39) pp:NaN4330-4330
Publication Date(Web):2012/12/03
DOI:10.1039/C2CC37963E
Metabolic chemical reporters of glycosylation allow for the visualization and identification of a variety of glycoconjugates by taking advantage of the promiscuity of carbohydrate metabolism. Here we describe the synthesis and characterization of metabolic chemical reporters bearing an N-propargyloxycarbamate (Poc) group that creates discrimination between glycosylation pathways.
GUANIDINE CARBONATE
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-β-D-glucopyranose
D-Glucose, 2-azido-2-deoxy-
Acetylglucosaminyltransferase,uridine diphosphoacetylglucosamine-glycoprotein serine/threonine
6-DEOXY-GALACTOSE
D-Galactopyranose, 2-[(2-azidoacetyl)amino]-2-deoxy-, 1,3,4,6-tetraacetate
4-Pentynoic acid, anhydride
D-Glucose, 2-(acetylamino)-6-azido-2,6-dideoxy-